JP2014205708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014205708A5 JP2014205708A5 JP2014139140A JP2014139140A JP2014205708A5 JP 2014205708 A5 JP2014205708 A5 JP 2014205708A5 JP 2014139140 A JP2014139140 A JP 2014139140A JP 2014139140 A JP2014139140 A JP 2014139140A JP 2014205708 A5 JP2014205708 A5 JP 2014205708A5
- Authority
- JP
- Japan
- Prior art keywords
- obesity
- compound
- seq
- ser
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 208000008589 Obesity Diseases 0.000 claims 10
- 235000020824 obesity Nutrition 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000000923 atherogenic effect Effects 0.000 claims 2
- 208000012696 congenital leptin deficiency Diseases 0.000 claims 2
- 208000020694 gallbladder disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000001022 morbid obesity Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920000642 polymer Chemical group 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014139140A JP5912151B2 (ja) | 2014-07-04 | 2014-07-04 | グルカゴン類似体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014139140A JP5912151B2 (ja) | 2014-07-04 | 2014-07-04 | グルカゴン類似体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540189A Division JP5635531B2 (ja) | 2008-12-15 | 2008-12-15 | グルカゴン類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014205708A JP2014205708A (ja) | 2014-10-30 |
| JP2014205708A5 true JP2014205708A5 (enExample) | 2015-01-22 |
| JP5912151B2 JP5912151B2 (ja) | 2016-04-27 |
Family
ID=52119561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014139140A Expired - Fee Related JP5912151B2 (ja) | 2014-07-04 | 2014-07-04 | グルカゴン類似体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5912151B2 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2471810A1 (en) * | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| KR20090119876A (ko) * | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| CA2747155A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
-
2014
- 2014-07-04 JP JP2014139140A patent/JP5912151B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6200025B2 (ja) | 心臓病の処置 | |
| TWI608013B (zh) | 升糖素類似物 | |
| TWI670281B (zh) | Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法 | |
| JP6396211B2 (ja) | 新規化合物及び摂食行動に対するそれらの効果 | |
| JP5669395B2 (ja) | 新規化合物および摂食行動に対するその効果 | |
| JP2013523619A5 (enExample) | ||
| JP2013517307A5 (enExample) | ||
| JP2017505284A5 (enExample) | ||
| FI3558361T3 (fi) | Myostatiini-, aktiviini- tai aktiviinireseptorin antagonisteja käytettäviksi lihavuuden ja siihen liittyvien tilojen hoidossa | |
| CY1120781T1 (el) | Καινοτομα παραγωγα οξυντομοντουλινης και φαρμακευτικη συνθεση αντιμετωπισης της παχυσαρκιας που τα περιεχει | |
| JP2019112437A (ja) | グルカゴン類似体 | |
| JP2019510739A5 (enExample) | ||
| JP2014534220A5 (enExample) | ||
| RU2017145348A (ru) | Селективные соединения пептида yy и их применения | |
| JP2011503152A5 (enExample) | ||
| JP2015524419A5 (enExample) | ||
| MX2013011674A (es) | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. | |
| JP2012509687A5 (enExample) | ||
| JP2015520184A5 (enExample) | ||
| RU2013120135A (ru) | Глюкозозависимые инсулинотропные пептидные аналоги | |
| JP2019515908A5 (enExample) | ||
| BR112013030067A2 (pt) | "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo" | |
| JP2011528334A5 (enExample) | ||
| JP2007500222A5 (enExample) | ||
| EP4126004A1 (en) | Agonist combination |